A Drug Class That Works Differently When There Are Testes in the Room
A well-meaning primary care physician started him on the same aromatase inhibitor his sister took for her own breast cancer. The pharmacology of that drug class doesn't translate as cleanly across sexes as the shared diagnosis suggests it should.
Walter O., a 71-year-old retired volunteer fire chief who spent twenty-two years running toward the calls other people ran away from, found his own diagnosis almost by accident — a firm area under the nipple his wife noticed while helping him change a bandage after a minor fall. His tumor came back strongly hormone-receptor-positive, closely echoing his sister's own breast cancer three years earlier, and his primary care physician, reasoning from that shared diagnosis, started him on anastrozole — the same aromatase inhibitor his sister had taken — six weeks before his oncology referral actually happened.
Aromatase inhibitors work by blocking the peripheral conversion of androgens to estrogen, which is the near-total source of circulating estrogen in a postmenopausal woman once ovarian production has stopped — but men retain an ongoing, separate estrogen source that women past menopause don't: testicular Leydig cells continue producing testosterone, some of which is aromatized locally and peripherally regardless of what an aromatase inhibitor is doing elsewhere in the body, and rising luteinizing hormone in response to falling estrogen can actually increase testicular androgen substrate available for aromatization, partially undermining the drug's own intended effect. Retrospective and registry data have consistently found tamoxifen outperforming aromatase-inhibitor monotherapy in men — Eggemann and colleagues, analyzing 257 men from German population-based registries, found aromatase-inhibitor treatment carried roughly a 1.5-fold higher adjusted mortality risk than tamoxifen, and the EORTC 10085 International Male Breast Cancer Program reached the same practical conclusion, a finding that tracks directly with this mechanistic gap rather than contradicting it — tamoxifen works by blocking the estrogen receptor itself, a mechanism that doesn't depend on how much estrogen is circulating in the first place, sidestepping the incomplete-suppression problem an aromatase inhibitor runs into in a male patient. Walter's current regimen isn't simply the second-best option; for his sex specifically, it's treating a source of estrogen that an aromatase inhibitor alone doesn't fully shut off.
Medical oncology, treatment reassignment
The mechanistic gap here is well-established, not a theoretical concern: aromatase inhibitor monotherapy in men doesn't achieve the same estrogen suppression it does in postmenopausal women, because testicular aromatization isn't addressed by the drug at all. I want to switch him to tamoxifen now rather than continue a regimen built for a physiology he doesn't have.
I want to be transparent about my own reasoning so it's corrected properly rather than just reversed: I matched his prescription to his sister's regimen because the pathology reports looked identical, and I didn't know the sex-specific pharmacology differed this much for a drug class I'd have called interchangeable with tamoxifen in a postmenopausal woman.
That's a completely understandable read from the oncology side of things looking similar — the actual gap is that "hormone-receptor-positive" describes the tumor, not the hormonal environment feeding it, and those turn out to be two different questions once sex is in the picture.
One practical note relevant to switching him: his benign prostatic hyperplasia and tamsulosin use don't interact meaningfully with tamoxifen pharmacologically, so there's no urologic reason to hesitate on the switch — I'd just want his usual BPH follow-up to continue on schedule rather than assume the oncology visit covers that ground too.
Agreed: tamoxifen replaces anastrozole, with a brief written explanation sent back to his primary care physician documenting the mechanistic reasoning, so the same substitution isn't made again for a future male patient.